Actively Recruiting
Phase 3 Multicenter Study Comparing Inebilizumab IV Infusion and Oral Tacrolimus in Adults With Primary Membranous Nephropathy
Led by Amgen · Updated on 2026-10-01
159
Participants Needed
4
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy of inebilizumab in adults with primary membranous nephropathy PMN, a kidney condition characterized by disease activity affecting kidney function. This phase 3, open-label, randomized study aims to measure the percentage of participants achieving complete remission of PMN by week 104. The trial compares inebilizumab to tacrolimus, an active comparator, to assess treatment effects on disease activity and remission rates. Participants receive either inebilizumab through intravenous infusion or tacrolimus taken orally. The study follows a parallel design where participants are randomly assigned to one of these treatments. The treatment phase extends up to 104 weeks, during which multiple outcome measures, including remission status, antibody levels, kidney function, and quality of life, are assessed. Safety is monitored throughout, with tracking of adverse events up to week 194. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio, antibody testing, kidney function tests, and patient-reported outcome questionnaires. Researchers measure complete and partial remission rates, time to remission, relapse, and changes in quality of life related to kidney disease. Safety evaluations monitor adverse events and antibody development. Participation lasts up to approximately four years, allowing long-term observation of treatment effects and safety.
CONDITIONS
Brief Title
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here